Expansion and profits ?The market will come to reality when TH\THERF will announce that a modification of the label is sent to FDA for the US market. And if the sales of EGRIFTA by then surge in the US following the study.
But the market is reacting quite accurately right now with this question : Theres a lot of things coming up for the company that MEANS COSTS: Europe (team; sales people); Label expansion; studies; KATANA pipeline;......Will TH\THERF be able in the next quarters to SHOW A PROFIT IN THE BOTTOM LINE.
As we saw, in july, with the trend in sales for TROGARZO, the two drugs will be selling at an equal amount in US $.
Market was calling a 2 cents profit per share. We where down 2 cents. Thats 4 cents a share difference.
And for the market, that means 5% down yesterday with big volume (sellers). And neutral today. And no volume.
FTV.